Indaptus Therapeutics (NASDAQ:INDP) Stock Rating Reaffirmed by HC Wainwright

Indaptus Therapeutics (NASDAQ:INDPGet Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 381.93% from the company’s current price.

Indaptus Therapeutics Trading Down 5.7 %

Shares of NASDAQ:INDP opened at $2.49 on Monday. The company has a market capitalization of $21.26 million, a price-to-earnings ratio of -1.40 and a beta of 1.30. Indaptus Therapeutics has a 12 month low of $1.56 and a 12 month high of $4.08. The firm’s 50-day moving average is $2.39 and its 200 day moving average is $2.10.

Indaptus Therapeutics (NASDAQ:INDPGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.12. As a group, equities analysts forecast that Indaptus Therapeutics will post -1.83 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDPFree Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,232 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned 0.17% of Indaptus Therapeutics at the end of the most recent reporting period. 7.06% of the stock is owned by institutional investors.

About Indaptus Therapeutics

(Get Free Report)

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.

Recommended Stories

Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with's FREE daily email newsletter.